Navigation Links
AMDL Announces First Quarter 2008 Results Posting Sales of $3.58 Million
Date:5/15/2008

- Revenues from Product Sales Increased 149% to $3.5 Million -

- Gross Profit Up; Net Loss Down -

TUSTIN, Calif., May 15 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL) is a vertically integrated specialty pharmaceutical company headquartered in Tustin, California, with operations in Shenzhen, Jiangxi and Jilin China. Through its wholly owned subsidiary Jade Pharmaceutical Inc. (JPI), the Company engages in the research, development, manufacture, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products currently in the People's Republic of China. AMDL announced today that it had sales of approximately $3.58 million (unaudited) for the first quarter of 2008 compared to $1.4 million for the first quarter of 2007. It should be noted that first quarter sales are typically the lowest of the year due to Chinese holidays, which last for several weeks, and general industry trends. Please see AMDL's Form 10-Q for the period ended March 31, 2008 for more information.
The First Quarter 2008 Financial Highlights (unaudited) include:

-- Gross Profit. AMDL gross profit for the three months ended March 31,

2008 increased 144% to $1,771,016, compared to $726,869 for the same

period in 2007. JPI contributed $1,769,593 to the gross profit for

the three months ended March 31, 2008, compared to $715,299 for the

same period in 2007.

-- Loss from Operations and Net Loss. AMDL consolidated net loss for the

three months ended March 31, 2008 was $1,472,196 or ($0.10) per share,

compared to a consolidated net loss of $1,385,406 or ($0.14) per share

for the same period in 2007.

Gary Dreher, CEO of AMDL, stated that, "The continued improvements in AMDL's China operations, combined with other recently announced business opportunities create a financial platform for us to improve our sales and earnings profile during the remainder of FY2008 and beyond. This gives us greater confidence in AMDL's continued positive financial performance over the next year." AMDL's 2007 results as well as business improvement and opportunities referenced above include:

-- FY2007 Sales of $15 Million and Gross Profits of $8.1 million;

-- In-licensed MyGene's Human Papilloma Virus (HPV) Diagnostic Test;

-- Signed LOI for the purchase of a China based pharmaceutical

distribution company with $28.55 million in revenue, approximately 10%

NOI and 20-30% growth rate;

-- Signed MOU with Hau Du Beauty Co., Ltd for its 200 stores to

distribute Jade's Goodnak Product Line;

-- AMDL launched a new updated website at http://www.amdl.com.

About AMDL: More information about AMDL and its products can be obtained at http://www.amdl.com. AMDL, together with Jade, engages in the development, manufacture and marketing of proprietary pharmaceutical and diagnostic products.

About Jade Pharmaceuticals Inc.: JPI has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its Jade subsidiaries, currently holds licenses for 133 products that are manufactured as large volume injection fluids, tablets and other related products. It currently manufactures over 20 key generic, over-the-counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards.

Forward-looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

Contact: AMDL, Inc.

Mr. Paul Knopick

AMDL Investor Relations

Direct Line: 949.707.5365

Voice Mail: 714.505.4460


'/>"/>
SOURCE AMDL, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioMS Medical announces first quarter 2008 results
2. Bioheart, Inc. Announces Financial Results for First Quarter 2008
3. BioElectronics Announces Conference Call to Update Investors on Growth Initiatives
4. KV Pharmaceutical Company Announces Approval for the 50 mg Strength of Generic Version of Toprol-XL(R)
5. Vermillion Announces First Quarter 2008 Financial Results and Business Progress
6. Surface Logix Announces Executive Management Changes
7. Huifeng Bio-Pharmaceutical (HFGB) Announces No Earthquake Related Damage to Facilities
8. Boston Scientific Announces Program to Analyze Latitude(R) Patient Monitoring Data
9. China Biologic Products Announces First Quarter 2008 Results Conference Call
10. 3SBio Inc. Announces First Quarter 2008 Results
11. LifeStem International, Inc. Announces Increased Revenues, Decreased Operating Expenses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... ... delivering cutting-edge information focused on the development and manufacture of biopharmaceuticals and ... premier sponsor of the 2016 BioProcess International Awards – Recognizing Excellence in ...
(Date:2/11/2016)... MIAMI (PRWEB) , ... February 11, 2016 , ... ... in regenerative medicine, has announced a new agreement with Bankok,Thailand-based Global Stem Cells ... researchers and phsyicians in 15 Latin American countries, including Mexico, Costa Rica, Dominican ...
(Date:2/10/2016)... 2016 NX Prenatal Inc., a US ... technology for early warning of adverse pregnancy outcomes, ... study by Dr. Thomas McElrath of ... Fetal Medicine,s (SMFM) annual meeting held in ... 2016.  The presentation reported initial positive top-line results ...
(Date:2/10/2016)... , Feb. 10, 2016  Matchbook, Inc., ... for fast growing biotech companies, announced today the ... Procurement Strategic Advisor. Jim brings nearly 25 years ... and procurement, having spent nearly two decades in ... Chain/Logistics and Procurement at Genzyme and, most recently ...
Breaking Biology Technology:
(Date:1/21/2016)... , January 21, 2016 ... to a new market research report "Emotion Detection and ... Others), Software Tools (Facial Expression, Voice Recognition and ... - Global forecast to 2020", published by MarketsandMarkets, ... expected to reach USD 22.65 Billion by 2020, ...
(Date:1/20/2016)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is pleased to announce the attainment of record-setting corporate ... of the company,s laser focus on (and growing international ... comprehensive, easy-to-use and highly affordable cloud-based technology platform. ... growth achievements in 2015 include: , Record ...
(Date:1/18/2016)... Calif. , Jan. 18, 2016  Extenua ... software that simplifies the use and access of ... and go-to-market partnership with American Cyber.  ... brings extensive experience leading transformational C4ISR and Cyber ... and integrating the latest proven technology solutions," said ...
Breaking Biology News(10 mins):